Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis

Detalhes bibliográficos
Autor(a) principal: Feitosa, Juliana Santos
Data de Publicação: 2024
Outros Autores: Barreto, Natália Araújo, Andrade, Talita Santos, Oliveira, Glauber Amaral de, Oliveira, Larissa Marrocos de, Lima, Tarcisio Brandão
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/45540
Resumo: Objective: To systematically review the evidence on the use of melatonin in the treatment of sleep disorders in children and adolescents with autism spectrum disorder (ASD). Method: Systematic review of randomized controlled clinical trials on the use of melatonin and included children and adolescents with ASD and sleep disorders, searching MEDLINE, SCOPUS, Web of science, Cochrane Central Register Controlled Trials, in the period between September and October 2023. The selection of studies were carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Changes in Total Sleep Time (TST) and Sleep Latency (SL) measurements were statistically significant. The 95% CI of 1.66 [1.10, 2.23] and 2.55 [1.02, 4.08] showed an increase in TST with the use of the intervention. (p < 0.00001) [18, 19]. Garstang showed a statistical difference with the use of melatonin, with the result of 95% CI of -5.96 [-8.77, -3.16], as well as Cortesi with a 95% CI of -1.23 [-1.75, - 0.70] and Gringras with -1.35 [-1.79, -0.91], with reduced latency to start sleep (p = 0.0002). Conclusions: Larger samples are needed to evaluate the effectiveness of melatonin on other sleep patterns, such as nighttime awakenings and sleep quality.
id UNIFEI_1f99b82a78e60a1b4da0570a2e5953fe
oai_identifier_str oai:ojs.pkp.sfu.ca:article/45540
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisisMelatonina versus placebo no tratamento de distúrbios do sono em crianças e adolescentes com autismo: Revisão sistemática com meta-análiseMelatonin versus placebo in the treatment of sleep disorders in children and adolescents with autism: Systematic review and meta-analysisInsomnioNiñosMelatoninaDesorden del espectro autistaEnsayo clínico.InsôniaCriançasMelatoninaTranstorno do espectro do autismoEnsaios clínicos.InsomniaChildrenMelatoninAutism spectrum disorderClinical trial.Objective: To systematically review the evidence on the use of melatonin in the treatment of sleep disorders in children and adolescents with autism spectrum disorder (ASD). Method: Systematic review of randomized controlled clinical trials on the use of melatonin and included children and adolescents with ASD and sleep disorders, searching MEDLINE, SCOPUS, Web of science, Cochrane Central Register Controlled Trials, in the period between September and October 2023. The selection of studies were carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Changes in Total Sleep Time (TST) and Sleep Latency (SL) measurements were statistically significant. The 95% CI of 1.66 [1.10, 2.23] and 2.55 [1.02, 4.08] showed an increase in TST with the use of the intervention. (p < 0.00001) [18, 19]. Garstang showed a statistical difference with the use of melatonin, with the result of 95% CI of -5.96 [-8.77, -3.16], as well as Cortesi with a 95% CI of -1.23 [-1.75, - 0.70] and Gringras with -1.35 [-1.79, -0.91], with reduced latency to start sleep (p = 0.0002). Conclusions: Larger samples are needed to evaluate the effectiveness of melatonin on other sleep patterns, such as nighttime awakenings and sleep quality.Objetivo: Revisar sistemáticamente la evidencia sobre el uso de melatonina en el tratamiento de los trastornos del sueño en niños y adolescentes con trastorno del espectro autista (TEA). Método: Revisión sistemática de ensayos clínicos controlados aleatorios sobre el uso de melatonina e incluyeron niños y adolescentes con TEA y trastornos del sueño, buscando en MEDLINE, SCOPUS, Web of science, Cochrane Central Register Controlled Trials, en el período comprendido entre septiembre y octubre de 2023. La selección de estudios se llevó a cabo utilizando los elementos de informes preferidos para revisiones sistemáticas y metanálisis (PRISMA). Resultados: Los cambios en las mediciones del tiempo total de sueño (TST) y la latencia del sueño (SL) fueron estadísticamente significativos. El IC del 95% de 1,66 [1,10, 2,23] y 2,55 [1,02, 4,08] mostró un aumento en la TST con el uso de la intervención. (p <0,00001) [18, 19]. Garstang mostró diferencia estadística con el uso de melatonina, con el resultado de IC 95% de -5.96 [-8.77, -3.16], así como Cortesi con un IC 95% de -1.23 [-1.75, - 0.70] y Gringras con -1,35 [-1,79, -0,91], con latencia reducida para iniciar el sueño (p = 0,0002). Conclusiones: Se necesitan muestras más amplias para evaluar la eficacia de la melatonina sobre otros patrones de sueño, como los despertares nocturnos y la calidad del sueño.Objetivo: Revisar sistematicamente as evidências sobre o uso da melatonina no tratamento de distúrbios do sono em crianças e adolescentes com transtorno do espectro do autismo (TEA). Método: Revisão sistemática de ensaios clínicos randomizados controlados sobre o uso de melatonina e incluídos crianças e adolescentes com TEA e distúrbios do sono, pesquisando MEDLINE, SCOPUS, Web of science, Cochrane Central Register Controlled Trials, no período entre setembro e outubro de 2023. O a seleção dos estudos foi realizada por meio do Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Resultados: As alterações nas medidas do Tempo Total de Sono (TTS) e da Latência do Sono (SL) foram estatisticamente significativas. O IC 95% de 1,66 [1,10; 2,23] e 2,55 [1,02; 4,08] mostrou aumento do PT com o uso da intervenção. (p < 0,00001) [18, 19]. Garstang apresentou diferença estatística com o uso de melatonina, com resultado de IC 95% de -5,96 [-8,77, -3,16], assim como Cortesi com IC 95% de -1,23 [-1,75, -0,70] e Gringras com -1,35 [-1,79, -0,91], com latência reduzida para iniciar o sono (p = 0,0002). Conclusões: São necessárias amostras maiores para avaliar a eficácia da melatonina em outros padrões de sono, como despertares noturnos e qualidade do sono.Research, Society and Development2024-04-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/4554010.33448/rsd-v13i4.45540Research, Society and Development; Vol. 13 No. 4; e6213445540Research, Society and Development; Vol. 13 Núm. 4; e6213445540Research, Society and Development; v. 13 n. 4; e62134455402525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/45540/36280Copyright (c) 2024 Juliana Santos Feitosa; Natália Araújo Barreto; Talita Santos Andrade; Glauber Amaral de Oliveira; Larissa Marrocos de Oliveira; Tarcisio Brandão Limahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFeitosa, Juliana Santos Barreto, Natália Araújo Andrade, Talita Santos Oliveira, Glauber Amaral de Oliveira, Larissa Marrocos de Lima, Tarcisio Brandão 2024-04-04T18:36:37Zoai:ojs.pkp.sfu.ca:article/45540Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-04-04T18:36:37Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
Melatonina versus placebo no tratamento de distúrbios do sono em crianças e adolescentes com autismo: Revisão sistemática com meta-análise
Melatonin versus placebo in the treatment of sleep disorders in children and adolescents with autism: Systematic review and meta-analysis
title Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
spellingShingle Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
Feitosa, Juliana Santos
Insomnio
Niños
Melatonina
Desorden del espectro autista
Ensayo clínico.
Insônia
Crianças
Melatonina
Transtorno do espectro do autismo
Ensaios clínicos.
Insomnia
Children
Melatonin
Autism spectrum disorder
Clinical trial.
title_short Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
title_full Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
title_fullStr Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
title_full_unstemmed Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
title_sort Melatonina versus placebo en el tratamiento de los trastornos del sueño en niños y adolescentes con autismo: Revisión sistemática y metanálisis
author Feitosa, Juliana Santos
author_facet Feitosa, Juliana Santos
Barreto, Natália Araújo
Andrade, Talita Santos
Oliveira, Glauber Amaral de
Oliveira, Larissa Marrocos de
Lima, Tarcisio Brandão
author_role author
author2 Barreto, Natália Araújo
Andrade, Talita Santos
Oliveira, Glauber Amaral de
Oliveira, Larissa Marrocos de
Lima, Tarcisio Brandão
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Feitosa, Juliana Santos
Barreto, Natália Araújo
Andrade, Talita Santos
Oliveira, Glauber Amaral de
Oliveira, Larissa Marrocos de
Lima, Tarcisio Brandão
dc.subject.por.fl_str_mv Insomnio
Niños
Melatonina
Desorden del espectro autista
Ensayo clínico.
Insônia
Crianças
Melatonina
Transtorno do espectro do autismo
Ensaios clínicos.
Insomnia
Children
Melatonin
Autism spectrum disorder
Clinical trial.
topic Insomnio
Niños
Melatonina
Desorden del espectro autista
Ensayo clínico.
Insônia
Crianças
Melatonina
Transtorno do espectro do autismo
Ensaios clínicos.
Insomnia
Children
Melatonin
Autism spectrum disorder
Clinical trial.
description Objective: To systematically review the evidence on the use of melatonin in the treatment of sleep disorders in children and adolescents with autism spectrum disorder (ASD). Method: Systematic review of randomized controlled clinical trials on the use of melatonin and included children and adolescents with ASD and sleep disorders, searching MEDLINE, SCOPUS, Web of science, Cochrane Central Register Controlled Trials, in the period between September and October 2023. The selection of studies were carried out using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results: Changes in Total Sleep Time (TST) and Sleep Latency (SL) measurements were statistically significant. The 95% CI of 1.66 [1.10, 2.23] and 2.55 [1.02, 4.08] showed an increase in TST with the use of the intervention. (p < 0.00001) [18, 19]. Garstang showed a statistical difference with the use of melatonin, with the result of 95% CI of -5.96 [-8.77, -3.16], as well as Cortesi with a 95% CI of -1.23 [-1.75, - 0.70] and Gringras with -1.35 [-1.79, -0.91], with reduced latency to start sleep (p = 0.0002). Conclusions: Larger samples are needed to evaluate the effectiveness of melatonin on other sleep patterns, such as nighttime awakenings and sleep quality.
publishDate 2024
dc.date.none.fl_str_mv 2024-04-16
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/45540
10.33448/rsd-v13i4.45540
url https://rsdjournal.org/index.php/rsd/article/view/45540
identifier_str_mv 10.33448/rsd-v13i4.45540
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/45540/36280
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 13 No. 4; e6213445540
Research, Society and Development; Vol. 13 Núm. 4; e6213445540
Research, Society and Development; v. 13 n. 4; e6213445540
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052639866781696